Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed inAustralia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody,...

2024-03-26 09:57 1058

BioDuro-Sundia's Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167

SHANGHAI, March 26, 2024 /PRNewswire/ -- BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has been approved by Korea Food and Drug Administration (MFDS) for Investigational New Drug ...

2024-03-26 08:30 1041

ANNOUNCEMENT OF 2023 ANNUAL RESULTS OF TONG REN TANG TECHNOLOGIES

BEIJING, March 25, 2024 /PRNewswire/ -- Tong Ren Tang Technologies Co. Ltd. (" Tong Ren Tang Technologies" or the "Group", 1666.HK) is pleased to announce the audited consolidated results of the Group for the year ended31 December 2023. In 2023, the Group's revenue amounted to RMB6.77 billion, rep...

2024-03-25 12:47 1790

Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider

SINGAPORE, March 25, 2024 /PRNewswire/ -- Juniper Biologics

2024-03-25 09:51 733

Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB

AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures CANBERRA, Australia, March 25, 2024 /PRNewswire/ -- The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Pro...

2024-03-25 08:04 694

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding it...

2024-03-22 19:00 3331

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine

SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published o...

2024-03-22 18:42 2433

Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline

* Promising clinical activities and efficacies during dose escalations for four lead global rights programs targeting CD24, Claudin 18.2, CD73, and PD-L1/4-1BB * Positive, differentiated cervical cancer data advancing mTORC1/2 inhibitor on registrational track for APAC markets * RMB1.188 bi...

2024-03-22 18:00 5788

OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth

SHANGHAI, March 21, 2024 /PRNewswire/ -- On the evening of March 21st, OcuMension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "OcuMension" or the "Company") disclosed its 2023 annual performance report. The company achieved a total operating income ofRMB 246.4 million ...

2024-03-21 22:44 3171

100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer

SAN FRANCISCO, March 21, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their ...

2024-03-21 20:30 1141

FDA Grants Orphan Drug Designation to Cevidoplenib for ITP

PANGYO, South Korea, March 21, 2024 /PRNewswire/ -- Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immune thrombocytopenia (ITP). Oscotec has successfully completed phase 2 study in patients wit...

2024-03-21 20:00 1274

Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved

SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit ofRMB546.0 million. This is the first time for Henlius to a...

2024-03-21 19:47 2972

Biosion to Present Three Posters at the 2024 AACR Meeting

NEWARK, Del. and NANJING, China, March 21, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage biotechnology company, today announced upcoming presentations of pre-clinical data for its oncology pipeline assets, including BSI-111, an anti-CD16a monoclonal antibody, BSI-730, a HER2/PD-L1 bispec...

2024-03-21 19:00 1093

HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update

* Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth. * R&D momentum persisted with promising developments in anti-FcRn antibodies HL161ANS and batoclimab, positioning them as potentially best-in-class treatments for lgG-mediated autoimmune diseases. * Anticip...

2024-03-21 19:00 1103

111, Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results

SHANGHAI, March 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the fourth qua...

2024-03-21 16:47 2338

Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London

SHANGHAI, March 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, published "Mtoxin™ Payload Applied in IDDC™ ADC Platform Significant Increases Therapeutic Index and Overcome MultiDrug Resistance in Various Tumor" as poster ...

2024-03-21 14:11 1153

Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London

Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...

2024-03-20 20:30 2071

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

* ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology inthe United States * The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary efficacy of ATN-031 in patients with advanced solid tumor...

2024-03-20 20:30 2134

Innovent Announces 2023 Annual Results and Business Updates

A transformative year of strong performance and material innovation progress ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

2024-03-20 19:44 3103

BGI Group Celebrates 20th Anniversary of Partnerships in Healthcare and Genomics in Thailand

BANGKOK, March 20, 2024 /PRNewswire/ -- This year marks the twentieth anniversary of BGI Group's close relationship with the Kingdom ofThailand. Initially both parties were brought together through an international humanitarian rescue effort during the Indian Ocean tsunami where BGI worked with ...

2024-03-20 12:39 1685

1 2 3 456 7 8 ... 292